In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.
Short-term safety profile of Sars-Cov2 vaccination on glucose control. Continuous glucose monitoring data in people with autoimmune diabetes / D'Onofrio, L.; Coraggio, L.; Zurru, A.; Carlone, A.; Mignogna, C.; Moretti, C.; Maddaloni, E.; Buzzetti, R.. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 179:(2021), pp. 1-3. [10.1016/j.diabres.2021.109022]
Short-term safety profile of Sars-Cov2 vaccination on glucose control. Continuous glucose monitoring data in people with autoimmune diabetes
D'Onofrio L.
;Coraggio L.;Zurru A.;Carlone A.;Mignogna C.;Moretti C.;Maddaloni E.;Buzzetti R.
2021
Abstract
In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.| File | Dimensione | Formato | |
|---|---|---|---|
|
DOnofrio_Short-term-safetyprofileSars-Cov2vaccination_ 2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
618.03 kB
Formato
Adobe PDF
|
618.03 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
